Clinical trials: Neurogenic Detrusor Overactivity, active
Spinal Cord Injuries, Neurogenic Detrusor Overactivity
TTNS in SCI Patients With Neurogenic Detrusor Overactivity
This is a prospective, single-arm, pilot study to assess effectiveness and tolerability of transcutaneous tibial nerve stimulation (TTNS) in managing neurogenic detrusor overactivity in spinal cord injury patients.
- Trial name
- NCT07785258
- Testing
- TTNS
- Where
- Singapore
- Volunteers
- 12 people
- Sponsor
- National University Hospital, Singapore
Neurogenic Bladder
Device for Bladder Control for Men With SCI
Urinary incontinence, bladder frequency, and bladder urgency are significant medical problems for people with overactive bladder (OAB) or neurogenic bladder overactivity (NDO).
- Trial name
- NCT07668063
- Testing
- Noninvasive electrical stimulation device to improve bladder control
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- VA Office of Research and Development
Spinal Cord Injuries (SCI)
The Predictive Value of Lower Extremity Hypertonia on Neurogenic Detrusor Overactivity After Spinal Cord Injury
The goal of this observational study is to evaluate whether increased lower extremity muscle tone can serve as an independent predictor of neurogenic detrusor overactivity (NDO) in adult patients (aged 18-80 years) with upper…
- Trial name
- NCT07695662
- Volunteers
- 300 people
- Sponsor
- Shengjing Hospital
Spinal Cord Injury, Acute
Transcutaneous Tibial Nerve Stimulation in Acute Spinal Cord Injury
Most patients with spinal cord injury (SCI) develop neurogenic lower urinary tract dysfunction (NLUTD), one of the most devastating sequelae of SCI which ultimately can lead to renal failure.
- Trial name
- TASCI (NCT03965299)
- Testing
- VERUM TTNS
- Where
- 4 sites in Switzerland
- Volunteers
- 114 people
- Sponsor
- University of Zurich
Spinal Cord Injuries, Neuromodulation
Improving Pelvic Rehabilitation Using Epidural Stimulation After Spinal Cord Injury
The investigators will recruit up to 20 volunteers with chronic, supra-sacral SCI. Following screening, eligible participants will enter 'Phase I', they will complete baseline outcome measures and then have the epidural spinal…
- Conditions
- Spinal Cord Injuries, Neuromodulation, Neurogenic Bladder, Neurogenic Bowel
- Trial name
- ImPRESS (NCT06515223)
- Testing
- Epidural Spinal Cord Stimulation
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- University College, London
Urinary Incontinence, Urinary Bladder, Neurogenic
Feasibility of Triggered Sacral Neuromodulation for Neurogenic Bladder
Incontinence associates with military service and post-traumatic stress disorder in both male and female Veterans. Neurogenic detrusor overactivity (NDO) is caused by spinal cord injury or disorder, or peripheral…
- Trial name
- NCT05141487
- Testing
- UroMonitor, ASCU
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- VA Office of Research and Development
Spinal Cord Injury, Detrusor Overacitivity
Effects of Sacral and Tibial Stimulation on Bladder Function in Subacute Suprasacral Spinal Cord Injury
Suprasacral spinal cord injury (SCI) frequently leads to neurogenic detrusor overactivity (NDO), resulting in elevated bladder storage pressures, urinary incontinence, and an increased risk of upper urinary tract damage.
- Trial name
- NCT07343583
- Testing
- Transcutaneous Tibial Nerve Stimulation, Transcutaneous Sacral Nerve Stimulation
- Where
- Turkey (Türkiye)
- Volunteers
- 45 people
- Sponsor
- Ankara City Hospital Bilkent
Neurogenic Detrusor Overactivity, Spinal Cord Injuries
Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization
This is a first-in-human, Phase 1b/2a, open-label, dose-escalation study of a single treatment course consisting of multiple intradetrusor injections of EG110A in male and female adult participants with Neurogenic Detrusor…
- Trial name
- NCT06596291
- Testing
- EG110A
- Where
- 5 sites in United States
- Volunteers
- 16 people
- Sponsor
- Cyllene Therapeutics
Neurogenic Detrusor Overactivity
Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC
The purpose of this study is to evaluate the safety, efficacy, and PK of Vibegron in pediatric participants with NDO who are regularly using CIC
- Trial name
- KANGUROO (NCT05491525)
- Testing
- Vibegron
- Where
- 38 sites in United States, Belgium and 14 more
- Volunteers
- 71 people
- Sponsor
- Urovant Sciences GmbH